Before starting enasidenib, it is crucial to conduct [genetic testing]() to confirm the presence of the IDH2 mutation. Patients should be monitored for signs of differentiation syndrome and managed promptly if symptoms occur. Additionally, liver function tests should be performed regularly due to the risk of elevated bilirubin levels.
